@article{2c4d86900f7340a88ea427631844a477,
title = "Liquid biopsy as surrogate for tissue for molecular profiling in pancreatic cancer: A meta-analysis towards precision medicine",
abstract = "Liquid biopsy (LB) is a non-invasive approach representing a promising tool for new precision medicine strategies for cancer treatment. However, a comprehensive analysis of its reliability for pancreatic cancer (PC) is lacking. To this aim, we performed the first meta-analysis on this topic. We calculated the pooled sensitivity, specificity, positive (LR+) and negative (LR-) likelihood ratio, and diagnostic odds ratio (DOR). A summary receiver operating characteristic curve (SROC) and area under curve (AUC) were used to evaluate the overall accuracy. We finally assessed the concordance rate of all mutations detected by multi-genes panels. Fourteen eligible studies involving 369 patients were included. The overall pooled sensitivity and specificity were 0.70 and 0.86, respectively. The LR+ was 3.85, the LR- was 0.34 and DOR was 15.84. The SROC curve with an AUC of 0.88 indicated a relatively high accuracy of LB for molecular characterization of PC. The concordance rate of all mutations detected by multi-genes panels was 31.9%. LB can serve as surrogate for tissue in the molecular profiling of PC, because of its relatively high sensitivity, specificity and accuracy. It represents a unique opportunity to be further explored towards its introduction in clinical practice and for developing new precision medicine approaches against PC.",
keywords = "CfDNA, Circulating tumor cells (CTC), Liquid biopsy, Pancreatic cancer, Precision medicine",
author = "Claudio Luchini and Nicola Veronese and Alessia Nottegar and Vera Cappelletti and Daidone, {Maria G.} and Lee Smith and Christopher Parris and Brosens, {Lodewijk A.A.} and Caruso, {Maria G.} and Liang Cheng and Wolfgang, {Christopher L.} and Wood, {Laura D.} and Michele Milella and Roberto Salvia and Aldo Scarpa",
note = "Funding Information: This work has been supported by University of Verona [personal funds for research] (C.L.), University of Verona Internalization Program ?Cooperint? (C.L., L.A.A.B.), Associazione Italiana Ricerca Cancro (AIRC) grant n. 12182 (A.S.), European Community Grant Transcan Bio-PaC (A.S.), FP7 European Community Grant Cam-Pac [no: 602783] (A.S.) and Italian Health Ministry [RF-2013-02359692] (M.G.D. and A.S.). The funding agencies had no role in the collection, analysis and interpretation of data, and in the writing of the manuscript. Funding Information: Funding: This work has been supported by University of Verona [personal funds for research] (C.L.), University of Verona Internalization Program “Cooperint” (C.L., L.A.A.B.), Associazione Italiana Ricerca Cancro (AIRC) grant n. 12182 (A.S.), European Community Grant Transcan Bio-PaC (A.S.), FP7 European Community Grant Cam-Pac [no: 602783] (A.S.) and Italian Health Ministry [RF-2013-02359692] (M.G.D. and A.S.). The funding agencies had no role in the collection, analysis and interpretation of data, and in the writing of the manuscript. Publisher Copyright: {\textcopyright} 2019 by the authors. Licensee MDPI, Basel, Switzerland.",
year = "2019",
month = aug,
doi = "10.3390/cancers11081152",
language = "English (US)",
volume = "11",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "8",
}